Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WESTLAKE VILLAGE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by
Toggle Summary Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Toggle Summary Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
WESTLAKE VILLAGE, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. , a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products

SEC Filings

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Refresh quote

Events

There are currently no events to display.

Transfer Agent

Wells Fargo Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com